NeuroMetrix Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>NE</div>
NURO -- USA Stock  

USD 2.02  0.10  5.21%

Today we may see the proof that Ekso Bionics would recover slower from the latest slide as its shares fell 3.49% to NeuroMetrix's 2.96%. As many millenniums are getting more into healthcare space, we are going to outline NeuroMetrix and Ekso Bionics as potential short-term trade. We are going to inspect some of the competitive aspects of both NeuroMetrix and Ekso Bionics.
Published over a month ago
View all stories for NeuroMetrix | View All Stories
Should we be picking up Ekso Bionics or NeuroMetrix?
By analyzing existing basic indicators between NeuroMetrix and Ekso Bionics, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Ekso Bionics with a short position in NeuroMetrix. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeuroMetrix has an asset utilization ratio of 64.59 percent. This suggests that the company is making $0.65 for each dollar of assets. An increasing asset utilization means that NeuroMetrix is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as NeuroMetrix or ElectroCore is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is NeuroMetrix's Liquidity

NeuroMetrix financial leverage refers to using borrowed capital as a funding source to finance NeuroMetrix ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NeuroMetrix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NeuroMetrix's total debt and its cash.

Correlation Between NeuroMetrix and ElectroCore

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding NeuroMetrix together with similar or unrelated positions with a negative correlation. For example, you can also add ElectroCore to your portfolio. If ElectroCore is not perfectly correlated to NeuroMetrix it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When NeuroMetrix for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between NURO and ECOR for more information.

Note

Are you currently holding both NeuroMetrix and ElectroCore in your portfolio? Please note if you are using this as a pair-trade strategy between NeuroMetrix and ElectroCore, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Purchase by Shai Gozani of 1000 shares of NeuroMetrix

Legal trades by NeuroMetrix insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NeuroMetrix insider trading alert for perchase of common stock by Shai Gozani, President & CEO, on 11th of June 2020. This event was filed by Neurometrix Inc with SEC on 2020-06-11. Statement of changes in beneficial ownership - SEC Form 4. Shai Gozani is currently serves as chairman of the board and presidentident, ceo, secretary of NeuroMetrix [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at NeuroMetrix

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now take a look at NeuroMetrix revenue. Based on the latest financial disclosure, NeuroMetrix reported 7.33 M of revenue. This is 99.9% lower than that of the Healthcare sector and 99.6% lower than that of the Medical Instruments & Supplies industry. The revenue for all United States stocks is 99.92% higher than that of the company. As for Ekso Bionics we see revenue of 10.77 M, which is 99.41% lower than that of the Medical Instruments & Supplies

Sector
1.8 B
NURO7.33 Million0.4
Sector1.84 Billion99.02
EKSO10.77 Million0.58

Our NeuroMetrix analysis suggests possible reversion in November

NeuroMetrix latest mean deviation surges over 2.9. NeuroMetrix exhibits very low volatility with skewness of 0.85 and kurtosis of 2.35. However, we advise investors to further study NeuroMetrix technical indicators to make sure all market info is available and is reliable.

Our Final Takeaway

Whereas few other entities in the medical instruments & supplies industry are either recovering or due for a correction, NeuroMetrix may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view, we believe it may be a good time to increase your existing holdings in NeuroMetrix as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NeuroMetrix.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of NeuroMetrix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com